The findings of this study resulted in the FDA approval of adjuvant atezolizumab on October 15, 2021, for resected stage II-IIIA NSCLC for patients whose tumors’ PD-L1 TPS is >= 1%. Here, CD274 is linked to non-small cell lung carcinoma.